autologous lymphoma cell vaccine + granulocyte-macrophage colony-stimulating factor-secreting K562 cells

This combination immunotherapy is a personalized cancer vaccine designed to treat various forms of Non-Hodgkin Lymphoma. The treatment consists of two primary components: irradiated autologous lymphoma cells collected from the patient and an irradiated bystander cell line, K562, which has been genetically engineered to secrete human granulocyte-macrophage colony-stimulating factor (GM-CSF). The autologous tumor cells provide a comprehensive, patient-specific library of tumor-associated antigens. The K562 bystander cells serve as a local cytokine production factory; upon administration, the secreted GM-CSF acts as a potent adjuvant to recruit and activate professional antigen-presenting cells, such as dendritic cells, to the injection site. These activated dendritic cells ingest the tumor antigens, migrate to regional lymph nodes, and prime a systemic, T-cell-mediated immune response against the patient's specific lymphoma cells. This bystander cell line approach avoids the need to genetically engineer each patient's individual tumor cells, streamlining the manufacturing process while maintaining a localized cytokine signal.

Other names

autologous tumor cell vaccine with GM-CSF-secreting K562 bystander cellsGM-K562 bystander vaccineGM-K-562 bystander vaccineGM-K 562 bystander vaccineGM-K562 lymphoma vaccineGM-K-562 lymphoma vaccineGM-K 562 lymphoma vaccine